CorEvitas Inflammatory Bowel Disease (IBD) Registry

Description

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

Conditions

Inflammatory Bowel Diseases

Talk to us

Study Overview

On this page

Study Details

Study overview

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

CorEvitas Inflammatory Bowel Disease (IBD) Registry

CorEvitas Inflammatory Bowel Disease (IBD) Registry

Condition
Inflammatory Bowel Diseases
Intervention / Treatment

-

Contacts and Locations

Waltham

CorEvitas, LLC, Waltham, Massachusetts, United States, 02451

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * At least 18 years of age or older.
  • * Willing and able to provide written consent for participation in the IBD Registry.
  • * Willing and able to provide Personally Identifiable Information (PII) which includes the following types of personal information at a minimum: full name, date of birth, sex, and home address zip code.
  • * Diagnosis of one of the following by a gastroenterologist:
  • 1. Crohn's disease
  • 2. Ulcerative colitis
  • * Prevalent users or new /incident users of an approved biologic drug or JAK inhibitor (Tofacitinib) for the treatment of UC or Crohn's disease.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

CorEvitas,

Jeffrey Greenberg, MD, STUDY_DIRECTOR, CorEvitas, LLC

Study Record Dates

2100-12